| Identification | Back Directory | [Name]
(S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(3,5-difluorophenyl)-5-oxopyrrolidine-2-carboxamide | [CAS]
1448346-43-7 | [Synonyms]
AGI14100
AGI-14100
AGI 14100
AGI-14100
(AGI14100)
(S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(3,5-difluorophenyl)-5-oxopyrrolidine-2-carboxamide | [Molecular Formula]
C29H22ClF4N5O3 | [MOL File]
1448346-43-7.mol | [Molecular Weight]
599.963 |
| Hazard Information | Back Directory | [Description]
AGI-14100 is a novel orally available mIDH1 inhibitor. Preclinical trials of AGI-14100 for the treatment of primary human myeloid leukemia therapy have been underway since 2013. |
|
|